scholarly journals Cutaneous Adverse Reactions and CD4+ Cell Counts in Human Immunodeficiency Virus–Infected Patients Receiving Trimethoprim‐Sulfamethoxazole

1998 ◽  
Vol 26 (2) ◽  
pp. 530-531 ◽  
Author(s):  
E. Caumes
Keyword(s):  
Human Immunodeficiency Virus ◽  
Adverse Reactions ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Immunodeficiency Virus ◽  
Cd4 Cell ◽  
Cutaneous Adverse Reactions

scholarly journals Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.

1996 ◽  
Vol 40 (11) ◽  
pp. 2664-2668 ◽  
Author(s):  
A M Been-Tiktak ◽  
I Williams ◽  
H M Vrehen ◽  
J Richens ◽  
D Aldam ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Transcriptase Inhibitor ◽  
Viral Loads ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Immunodeficiency Virus ◽  
Reverse Transcriptase Inhibitor ◽  
Cd4 Cell ◽  
Hiv 1

Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.

scholarly journals Acyclovir Use and Survival Among Human Immunodeficiency Virus‐Infected Patients with CD4 Cell Counts of < 500/mm

1998 ◽  
Vol 26 (1) ◽  
pp. 85-90 ◽  
Author(s):  
Ramón A. Torres ◽  
James D. Neaton ◽  
Deborah N. Wentworth ◽  
Michael R. Barr ◽  
Donald Abrams ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Immunodeficiency Virus ◽  
Cd4 Cell

scholarly journals Effect of Providing Vitamin Supplements to Human Immunodeficiency Virus–Infected, Lactating Mothers on the Child's Morbidity and CD4+Cell Counts

2003 ◽  
Vol 36 (8) ◽  
pp. 1053-1062 ◽  
Author(s):  
Wafaie W. Fawzi ◽  
Gernard I. Msamanga ◽  
Ruilan Wei ◽  
Donna Spiegelman ◽  
Gretchen Antelman ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Vitamin Supplements ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Lactating Mothers ◽  
Immunodeficiency Virus ◽  
Cd4 Cell

scholarly journals The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate [see comments]

Blood ◽  
1991 ◽  
Vol 78 (8) ◽  
pp. 1919-1922 ◽  
Author(s):  
R de Biasi ◽  
A Rocino ◽  
E Miraglia ◽  
L Mastrullo ◽  
AA Quirino
Keyword(s):  
Human Immunodeficiency Virus ◽  
High Purity ◽  
Skin Testing ◽  
Clinical Status ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Immunodeficiency Virus ◽  
Cd4 Cell ◽  
The Impact ◽  
Very High

Abstract Pathophysiologic considerations as well as non-comparative clinical results suggest that very high purity concentrates may slow immunologic deterioration in human immunodeficiency virus (HIV)-infected hemophiliacs. In an attempt to evaluate this hypothesis, we prospectively compared CD4 cell counts, skin testing responses, and changes of the clinical status in 20 asymptomatic HIV-positive hemophiliacs, randomly assigned to continue the treatment with an intermediate purity concentrate or to receive a very high purity product, purified by immunoaffinity chromatography with monoclonal antibodies. In the group switched to the very high purity concentrate there was no significant change of the CD4 cell counts over the 96-week follow-up period, whereas in the group continued on the intermediate purity concentrate, a highly significant decline was detected (P less than .013). Furthermore, in the very high purity group, four of six anergic patients at entry acquired reactivity to skin testing. The results of this study clearly support the use of very high purity concentrates for the replacement therapy of HIV-infected hemophiliacs.

Sign in / Sign up

Export Citation Format

Share Document